Phaseline

Targets › ANXA5

ANXA5 (Annexin A5): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology.

This protein is an anticoagulant protein that acts as an indirect inhibitor of the thromboplastin-specific complex, which is involved in the blood coagulation cascade. (UniProt, P08758)

Open in Phaseline: the race on ANXA5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Annexin PharmaceuticalsANXV
Human recombinant Annexin A5 protein; proposed mechanism involves binding to phosphatidyls
ANXA5Phase 2Non-Proliferative Diabetic Retinopathy–

Conditions

Non-Proliferative Diabetic Retinopathy (1)

Modalities

protein or peptide (1)

Companies

Annexin Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.